M
Matthias Karrasch
Researcher at University of Jena
Publications - 37
Citations - 1230
Matthias Karrasch is an academic researcher from University of Jena. The author has contributed to research in topics: Gene & Glioma. The author has an hindex of 11, co-authored 36 publications receiving 1059 citations. Previous affiliations of Matthias Karrasch include Schiller International University & MediGene.
Papers
More filters
Journal ArticleDOI
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
James M. Markert,Peter Liechty,Wenquan Wang,Shanna Gaston,Eunice Braz,Matthias Karrasch,Louis B. Nabors,Michael Markiewicz,Alfred D. Lakeman,Cheryl A. Palmer,Jacqueline N. Parker,Richard J. Whitley,George Yancey Gillespie +12 more
TL;DR: G207 appears safe for multiple dose delivery, including direct inoculation into the brain surrounding tumor resection cavity, and Radiographic and neuropathologic evidence suggestive of antitumor activity is reported.
Journal ArticleDOI
A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
James M. Markert,Shantanu N Razdan,Hui-Chien Kuo,Alan B. Cantor,Anette Knoll,Matthias Karrasch,L. Burt Nabors,Michael Markiewicz,Bonita S. Agee,Jennifer M. Coleman,Alfred D. Lakeman,Cheryl A. Palmer,Jacqueline N. Parker,Richard J. Whitley,Ralph R. Weichselbaum,John B. Fiveash,G. Yancey Gillespie +16 more
TL;DR: The safety and the potential for clinical response of single-dose oncolytic HSV therapy augmented with radiation in the treatment of malignant glioma patients are shown.
Journal ArticleDOI
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.
Nancy E. Kemeny,Karen T. Brown,Anne M. Covey,Teresa Kim,Amit Bhargava,Lynn A. Brody,Brenda Guilfoyle,Natasha P. Haag,Matthias Karrasch,Birgit Glasschroeder,Anette Knoll,George I. Getrajdman,K. Jon Kowal,William R. Jarnagin,Yuman Fong +14 more
TL;DR: It is concluded that NV1020, a genetically engineered but replication-competent HSV-1 oncolytic virus, can be safely administered into the hepatic artery without significant effects on normal liver function.
Journal ArticleDOI
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Andreas M. Kaufmann,John Nieland,Ingrid Jochmus,Ingrid Jochmus,S. Baur,Klaus Friese,Joseph Gabelsberger,Friederike Gieseking,Lutz Gissmann,Birgit Glasschröder,Thomas Grubert,Peter Hillemanns,Reinhard Höpfl,Hans Ikenberg,Jörg Schwarz,Matthias Karrasch,Anette Knoll,Volkmar Küppers,Martin Lechmann,Ralph J. Lellé,Harald Meissner,Rainer Muller,Michael Pawlita,Karl Ulrich Petry,Henryk Pilch,Elke Walek,Achim Schneider +26 more
TL;DR: Evidence for safety and a nonsignificant trend for the clinical efficacy of the HPV16 L1E7 CVLP vaccine is demonstrated.
Journal ArticleDOI
A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer
Yuman Fong,Teresa Kim,Amit Bhargava,Lawrence H. Schwartz,Karen T. Brown,Lynn A. Brody,Anne M. Covey,Matthias Karrasch,George I. Getrajdman,Axel Mescheder,William R. Jarnagin,Nancy E. Kemeny +11 more
TL;DR: Twelve subjects with metastatic colorectal cancer within the liver failing first-line chemotherapy were treated in four cohorts with a single dose of NV1020, a multimutated, replication-competent HSV, and no signs of virus reactivation were found during follow-up.